Global Antithrombotic/Anticoagulant Drugs Market Set to Reach $46.2 Billion by 2028 with a 7.9% CAGR
2023-11-06
DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to
ResearchAndMarkets.com's offering.
The global antithrombotic/anticoagulant drugs market is expected to reach $46.2 billion in 2028 from $31.6 billion in 2023 at a CAGR of 7.9%.
This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market.
Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market.
This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028.
Companies Mentioned
Report Includes
59 data tables and 35 additional tables
Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease
Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years
Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region
In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19
A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity
Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments
Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers
Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
Profiles of the leading market players
The following are the main conclusions reached in this report regarding antithrombotic and anticoagulant drugs:
Recent innovations and the emergence of novel thrombin inhibitorsthrombin inhibitors have led to the decrease in revenue of traditional anticoagulants such as heparin and Vitamin K antagonists. Low molecular weight heparins, such as Fragmin (-11.8%) and Innohep (-14.1%), have seen a significant decrease in the market.
The anticoagulant drug market will continue to grow at a slow rate compared to antiplatelet and thrombin inhibitors segment due to the lack of new drug launches since the expiration of the patent on Plavix. The anticoagulant segment is expected to decline soon as prices fall and the market for novel thrombin inhibitorsthrombin inhibitors grows.
The market for thrombin inhibitorsthrombin inhibitors is expected to grow at the highest CAGR of 8.1% over the forecast period of 2023 to 2028. Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban) are the major contributors to the high growth rate of thrombin inhibitorsthrombin inhibitors.
An aging population and the increased prevalence of cardiovascular disease worldwide fueled by a Westernized diet and lifestyle have created new opportunities for antithrombotic/ anticoagulant drug products.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Market Overview
Overview of Cardiovascular Disease
Atherosclerosis
Medical Management
Lifestyle Changes
Diet Modification
Smoking Cessation
Anticoagulants and Antiplatelet Drugs
Major Drivers
Coagulation Factors Targeted to Reduce Cvd
The Global Burden of Cardiovascular Disease
2030 Global Burden of Cardiovascular Disease
The Global Economic Burden of Cardiovascular Disease
Sales Performance of Major Drugs in 2022
Chapter 4 Global Market for Anticoagulant Drugs
Overview
Products
Low Molecular Weight Heparin
Oral Anticoagulants (Vitamin K Antagonists)
Global Anticoagulant Drugs Market Forecast
Chapter 5 Global Market for Antiplatelet Drugs
Overview
Products
Oral Antiplatelets
Global Antiplatelet Drugs Market Forecast
Chapter 6 Global Market for Thrombin InhibitorsThrombin Inhibitors
Overview
Products
Direct Thrombin Inhibitors
Thrombolytic Agents
Direct Factor Xa InhibitorsDirect Factor Xa Inhibitors
Global Thrombin InhibitorsThrombin Inhibitors Market Forecast
Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
Introduction to ESG
Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
Key ESG Issues
Consumer Attitudes Towards ESG
Industry ESG Performance Analysis
Case Study
Concluding Remarks
Chapter 9 Clinical Trials and Patent Landscape
Clinical Trials Analysis
Patent Analysis
Patent by Assignee
Chapter 10 M&A and Venture Funding Outlook
Chapter 11 Competitive Landscape
Chapter 12 Company Profiles
Chapter 13 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/h0sats
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。